[Interleukin-6 reflects the disease severity and prognosis of myeloma].
Pelliniemi
T T
TT
MediCity Research aboratory, Turku University Central Hospital, Finland.
Pulkki
K
K
D015415:Biomarkers / Q000097:blood*; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000032:analysis*; D008297:Male; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000188:drug therapy; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D019947:Receptors, Interleukin-6 / Q000037:antagonists & inhibitors*; D012680:Sensitivity and Specificity
D015415:Biomarkers; D015850:Interleukin-6; D019947:Receptors, Interleukin-6
Interleukiini 6 myelooman ennusteen arvioinnissa.